We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Microfluidic Silicon Probe Accurately Stains Tissue Sections

By LabMedica International staff writers
Posted on 24 Jan 2012
Print article
Image: The probe consists of a silicon microfluidic head having two microchannels. Unlike an inkjet printer cartridge, the head reaspirates the liquid that it injects on a surface. This prevents spreading and accumulation of the liquid on the surface, which can lead to overexposure (Photo courtesy of IBM).
Image: The probe consists of a silicon microfluidic head having two microchannels. Unlike an inkjet printer cartridge, the head reaspirates the liquid that it injects on a surface. This prevents spreading and accumulation of the liquid on the surface, which can lead to overexposure (Photo courtesy of IBM).
A flexible, noncontact microfluidic probe made from silicon can help pathologists to investigate critical tissue samples for disease diagnostics.

The microfluidic probe can accurately stain tissue sections at the micrometer scale. It consists of a silicon microfluidic head having two microchannels. Unlike an inkjet printer cartridge, the head reaspirates the liquid that it injects on a surface. This prevents spreading and accumulation of the liquid on the surface, which can lead to overexposure.

Specifically for tissue section analysis, the probe can deliver an antibody very locally in a selected area of a tissue section with pinpoint accuracy. Since analysis can be done on spots and lines instead of on the entire tissue section, the tissue is better preserved for additional tests, if required. In addition, only a few picoliters of liquid containing antibodies are needed for each analysis spot.

IBM (Zurich, Switzerland) scientists developed the microfluidic probe, which fits to standard workflows in conventional pathology. In addition, it is compatible with current biochemical staining systems and resistant to a broad range of chemicals. The small size of the probe also enables easy viewing of the sample from above and below by the inverted microscope commonly used in clinical laboratories.

"We have developed a proof-of-concept technology, which I hope puts pathology on a modern roadmap—benefiting from the latest developments in silicon-based microfluidics," said Govind Kaigala, a scientist at IBM Research-Zurich. He added, "This new approach will enable pathologists to stain tissue samples with micrometer precision and easily perform multiple tissue stains on limited samples."

IBM scientists will continue to test and improve the microfluidic probe and potentially begin using it in laboratory environments in the next several months. In addition, the team plans to explore specific clinical applications, possibly with partners in the field of pathology. The microfluidic probe promises to support the work of pathologists and become a tool of choice for pharmaceutical research and diagnostics involving biological specimens.

Related Links:

IBM Research, Zurich


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.